FDA approved Zyn without knowing its composition; microplastic shedding risk threatens PMI's fastest-growing product line.
FDA authorized Zyn nicotine pouches without knowing what they were made of, says former agency scientist
+0.64%open horizon
Speakerguest
Matthew Herper
@matthewherper / appears on tweets, tweets, tweets, tweets, tweets, tweets, tweets, tweets, tweets, tweets, tweets, tweets
Verified record
42credibility2 resolved
Speaker record
340B hits $100B as an accelerating gross-to-net drain on Lilly amid escalating reform battles and legal uncertainty
Sales from controversial U.S. drug discount program rose to $100B last year
+1.57%open horizon
FDA resumes CRL transparency after 2.5-month pause, dumping 14 new rejection letters onto small-cap biotech sector
FDA returns to releasing pharma rejection letters with 14 new CRLs
— pendingopen horizon
Vaccine-skeptic HHS ASPR nominee signals more federal pressure on hep-B and COVID shots, squeezing Merck's vaccine revenue.
Nominee for key federal health role has a history of questioning vaccines
Agent-readable speaker
{
"type": "trace.speaker",
"handle": "matthewherper",
"name": "Matthew Herper",
[
,
,
,
,
,
,
,
,
,
,
,
],
{
}
}AISO Market Calls classifies public statements from public sources. A classification such as long thesis, short thesis, or explicit call describes the content of the public statement and does not prove that the speaker actually entered, exited, or held a position. Market performance shown is calculated from public market data around the source publication or timestamp. It is not investment advice.